More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The new-look adjustable stents, not yet fully approved by the FDA, can be expanded as a child ages. The hope is that these stents will never need to be replaced.
Sean Fain, PhD, vice chair of radiology and research and a professor of radiology, University of Iowa, discusses how long-COVID lung damage can be tracked using xenon (Xe) gas MRI and quantitative CT at RSNA 2022.
The American College of Cardiology, American Heart Association, European Society of Cardiology and World Heart Federation all collaborated on a joint statement aimed at updating the rules and regulations associated with randomized clinical trials
Experts are hoping that, by imaging the dinosaur’s shoulder girdle and forelimb, they can create a digital model that could help in determining a T. Rex arm’s range of motion and strength.
Claustrophobic or not, most would choose the radiation-free modality over CT and tend to consider imaging-exam outcomes more worrisome than MRI in and of itself anyway.
